Acceleron (XLRN) reported a strong second quarter of 2020 on August 6. Revenue was $39.8 million, up sequentially from $4.3 million and up from the year-earlier figure of $27.7 million. Of that, Reblozyl royalty revenue in Q2 was $11.1 million, up sequentially from $1.5 million. Reblozyl (luspatercept) was first approved by the FDA for treatment of anemia related to beta thalassemia in late Q4 2019. The royalties are paid to Acceleron by Bristol-Myers Squibb (BMY).
Reblozyl royalty revenue has transformed Acceleron from a clinical-stage company to a commercial-stage pharmaceutical company. Looking